MiRSNPs are introduced as prognostic markers for MM patients undergoing ASCT for the first time as two specific miRSNPs—rs3660 in KRT81 and rs11077 in XPO5—that have a significant prognostic impact after ASCT. Here, XPO5 is linked to Miyoshi myopathy.